Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations is a new market research publication announced by Reportstack. The Type 1 Diabetes Mellitus (T1DM) market faces the threat of considerable biosimilar erosion over the forecast period, owing to recent and upcoming patent expirations for several of the leading insulin brands. These include Lantus (insulin glargine), marketed by Sanofi; Humalog (insulin lispro), marketed by Eli Lilly; and Levemir (insulin detemir) and Novolog (insulin aspart), both of which are marketed by Novo Nordisk. All of these companies, however, have strong pipeline products in development, and will therefore maintain their positions as dominant players in T1DM over the forecast period. Eli Lilly's Lantus biosimilar Basaglar has already been approved in most major markets, while several other biosimilars are in clinical development. Competitively priced biosimilars are anticipated to capture significant market shares from the leading brands over the forecast period.
Despite the impact of biosimilar erosion, the T1DM market is projected to experience robust growth over the forecast period, from $4.2 billion in 2014 to $7.1 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.9%. This is attributable to the fact that the incidence of T1DM is rising rapidly, at a rate of approximately 2-5% per year worldwide. Patients are also being diagnosed at younger ages, and are living longer due to improved treatment options. These trends will lead to an increase in the size of the treatment population over the forecast period.
Complete report with TOC available @ Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021.
"Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations" Type 1 Diabetes Mellitus is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and leads to hyperglycemia (high blood glucose levels).
- An introduction to T1DM, which includes classification, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment
- An analysis of the leading insulin therapies in the current T1DM marketed products landscape
- An analysis of the pipeline for T1DM. This includes a breakdown of pipeline molecules by stage of development, molecule type, route of administration, molecular target and novelty
- Forecast projections for the T1DM market to 2021. An analysis is provided for the global market and each of the eight major markets
- An analysis of strategic consolidations, including co-development and licensing deals, within the T1DM indication
Reportstack is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack members with cutting edge research products to facilitate strategic business decisions.
Manager - Marketing
Reportstack Market Research